A leader by this title appeared in the BMJ (BMJ 2006; 332:1103-4). It states what we already thought we did anyway - we need to lower lipids in all of our type 2 diabetic patients. Targets are now to reduce LDL cholesterol to <2mmol/l. It seems that for every 1mmol/l reduction in LDL-C there is a 21% reduction in cardiovascular events.
Statins would appear to be the lipid lowering drug group of choice, fibrates are second line. Even with statin therapy, 70% of cardiovascular events still occur.
So - we should be auditing our type 2 diabetics, checking that they are on statins and working out whether we are hitting the target for LDL-C reduction. Now there's a job for someone.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment